497 related articles for article (PubMed ID: 28377112)
21. Proarrhythmic risk assessment using conventional and new in vitro assays.
Goineau S; Castagné V
Regul Toxicol Pharmacol; 2017 Aug; 88():1-11. PubMed ID: 28506844
[TBL] [Abstract][Full Text] [Related]
22. Large-Scale Simulation of the Phenotypical Variability Induced by Loss-of-Function Long QT Mutations in Human Induced Pluripotent Stem Cell Cardiomyocytes.
Paci M; Casini S; Bellin M; Hyttinen J; Severi S
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30428582
[TBL] [Abstract][Full Text] [Related]
23. In silico assessment of the effects of various compounds in MEA/hiPSC-CM assays: Modeling and numerical simulations.
Abbate E; Boulakia M; Coudière Y; Gerbeau JF; Zitoun P; Zemzemi N
J Pharmacol Toxicol Methods; 2018; 89():59-72. PubMed ID: 29066291
[TBL] [Abstract][Full Text] [Related]
24. Automated Dynamic Clamp for Simulation of I
Becker N; Horváth A; De Boer T; Fabbri A; Grad C; Fertig N; George M; Obergrussberger A
Curr Protoc Pharmacol; 2020 Mar; 88(1):e70. PubMed ID: 31868992
[TBL] [Abstract][Full Text] [Related]
25. Application of human induced pluripotent stem cell-derived cardiomyocytes sheets with microelectrode array system to estimate antiarrhythmic properties of multi-ion channel blockers.
Izumi-Nakaseko H; Hagiwara-Nagasawa M; Naito AT; Goto A; Chiba K; Sekino Y; Kanda Y; Sugiyama A
J Pharmacol Sci; 2018 Aug; 137(4):372-378. PubMed ID: 30126708
[TBL] [Abstract][Full Text] [Related]
26. Triiodothyronine and dexamethasone alter potassium channel expression and promote electrophysiological maturation of human-induced pluripotent stem cell-derived cardiomyocytes.
Wang L; Wada Y; Ballan N; Schmeckpeper J; Huang J; Rau CD; Wang Y; Gepstein L; Knollmann BC
J Mol Cell Cardiol; 2021 Dec; 161():130-138. PubMed ID: 34400182
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological enhancement of repolarization reserve in human induced pluripotent stem cells derived cardiomyocytes.
Treat JA; Goodrow RJ; Bot CT; Haedo RJ; Cordeiro JM
Biochem Pharmacol; 2019 Nov; 169():113608. PubMed ID: 31465775
[TBL] [Abstract][Full Text] [Related]
28. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
Qu Y; Vargas HM
Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
[TBL] [Abstract][Full Text] [Related]
29. Recording of multiple ion current components and action potentials in human induced pluripotent stem cell-derived cardiomyocytes via automated patch-clamp.
Mann SA; Heide J; Knott T; Airini R; Epureanu FB; Deftu AF; Deftu AT; Radu BM; Amuzescu B
J Pharmacol Toxicol Methods; 2019; 100():106599. PubMed ID: 31228558
[TBL] [Abstract][Full Text] [Related]
30. Interpretation of field potentials measured on a multi electrode array in pharmacological toxicity screening on primary and human pluripotent stem cell-derived cardiomyocytes.
Tertoolen LGJ; Braam SR; van Meer BJ; Passier R; Mummery CL
Biochem Biophys Res Commun; 2018 Mar; 497(4):1135-1141. PubMed ID: 28153730
[TBL] [Abstract][Full Text] [Related]
31. Application of optical action potentials in human induced pluripotent stem cells-derived cardiomyocytes to predict drug-induced cardiac arrhythmias.
Lu HR; Hortigon-Vinagre MP; Zamora V; Kopljar I; De Bondt A; Gallacher DJ; Smith G
J Pharmacol Toxicol Methods; 2017 Sep; 87():53-67. PubMed ID: 28501647
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.
Paci M; Passini E; Severi S; Hyttinen J; Rodriguez B
Heart Rhythm; 2017 Nov; 14(11):1704-1712. PubMed ID: 28756098
[TBL] [Abstract][Full Text] [Related]
33. Characterization of Ventricular and Atrial Cardiomyocyte Subtypes from Human-Induced Pluripotent Stem Cells.
Nakanishi-Koakutsu M; Takaki T; Miki K; Yoshida Y
Methods Mol Biol; 2021; 2320():135-149. PubMed ID: 34302655
[TBL] [Abstract][Full Text] [Related]
34. Mutation-specific differences in arrhythmias and drug responses in CPVT patients: simultaneous patch clamp and video imaging of iPSC derived cardiomyocytes.
Pölönen RP; Swan H; Aalto-Setälä K
Mol Biol Rep; 2020 Feb; 47(2):1067-1077. PubMed ID: 31786768
[TBL] [Abstract][Full Text] [Related]
35. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
[TBL] [Abstract][Full Text] [Related]
36. Multielectrode Array Assays Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Yoshinaga D; Wuriyanghai Y; Makiyama T
Methods Mol Biol; 2021; 2320():111-119. PubMed ID: 34302653
[TBL] [Abstract][Full Text] [Related]
37. Overlap Arrhythmia Syndromes Resulting from Multiple Genetic Variations Studied in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Treat JA; Pfeiffer R; Barajas-Martinez H; Goodrow RJ; Bot C; Haedo RJ; Knox R; Cordeiro JM
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281161
[TBL] [Abstract][Full Text] [Related]
38. Establishment of an automated patch-clamp platform for electrophysiological and pharmacological evaluation of hiPSC-CMs.
Li W; Luo X; Ulbricht Y; Wagner M; Piorkowski C; El-Armouche A; Guan K
Stem Cell Res; 2019 Dec; 41():101662. PubMed ID: 31809994
[TBL] [Abstract][Full Text] [Related]
39. Repolarization instability and arrhythmia by IKr block in single human-induced pluripotent stem cell-derived cardiomyocytes and 2D monolayers.
Altrocchi C; de Korte T; Bernardi J; Spätjens RLHMG; Braam SR; Heijman J; Zaza A; Volders PGA
Europace; 2020 Sep; 22(9):1431-1441. PubMed ID: 32770183
[TBL] [Abstract][Full Text] [Related]
40. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.
Kitaguchi T; Moriyama Y; Taniguchi T; Ojima A; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Morita M; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Tanaka K; Washio I; Miyamoto N
J Pharmacol Toxicol Methods; 2016; 78():93-102. PubMed ID: 26657830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
